(Hypertension. 1995;26:164-170.)
© 1995 American Heart Association, Inc.
Articles |
Coronary Kinin Generation Mediates Nitric Oxide Release After Angiotensin Receptor Stimulation
From the Departments of Physiology and Pharmacology (A.N.), New York Medical College, Valhalla.
Correspondence to Thomas H. Hintze, PhD, New York Medical College, Valhalla, NY 10595.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract Our goal was to determine whether angiotensin II (Ang II) and its metabolic fragments release nitric oxide and the mechanisms by which this occurs in blood vessels from the canine heart. We incubated 20 mg of microvessels or large coronary arteries in phosphate-buffered saline for 20 minutes and measured nitrite release. Nitrite release increased from 27±2 up to 103±5, 145±17, 84±4, 107±16, and 54±4 pmol/mg (P<.05) in response to 10-5 mol/L of Ang I, II, III, IV, and Ang-(1-7), respectively. The effects of all angiotensins were blocked by N
-nitro-L-arginine methyl ester
(100 µmol/L), indicating that nitrite was a product of nitric oxide
metabolism, and by Hoe 140 (10 µmol/L), a specific bradykinin
B2 receptor antagonist, indicating a potential role for
local kinin formation. The protease inhibitors aprotinin (10 µmol/L)
and soybean trypsin inhibitor, which block local kinin formation,
inhibited nitrite release by all of the angiotensins. Angiotensin
nonselective (saralasin), type 1–specific (losartan), and type
2–specific (PD 123319) receptor antagonists abolished the nitrite
released in response to all the fragments. Angiotensin type 1 and type
2 and receptors mediate nitrite release after Ang I, II, III, and
Ang-(1-7), whereas only type 2 receptors mediate nitrite release after
Ang IV. Similar results were obtained in large coronary arteries.
In summary, formation of nitrite from coronary microvessels and large
arteries in the normal dog heart in response to angiotensin peptides is
due to the activation of local kinin production in the coronary vessel
wall.
Key Words: receptors, angiotensin • angiotensins • losartan • saralasin • aprotinin • nitrites
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin II (Ang II) is the primary mediator of the renin-angiotensin system and has an important functional role in cardiovascular homeostasis.1 2 Ang I is formed from angiotensinogen by circulating or local renin. Ang I, which is inactive, can be converted by angiotensin-converting enzyme in endothelial cells to Ang II. Whereas Ang II is a potent vasoconstrictor in a variety of vascular beds, angiotensin fragments that arise through metabolism were thought to be inactive. However, a recent study has shown that Ang II may be rapidly degraded to Ang-(1-7) in the brain of rats and dogs and that this fragment may be biologically active.3 Also, Ang IV may interact with endothelial cells to cause endothelial cell–dependent vasodilation,4 although a definitive function has not been assigned to this system. Therefore, in the present study our first aim was to determine the effect of Ang I, Ang II, and the angiotensin fragments (Ang III, Ang IV, and Ang-[1-7]) on nitric oxide (NO) release from the coronary vascular bed of the dog.
Prior studies have indicated the existence of a local kallikrein-kinin system in canine coronary arteries,5 in human cultured endothelial cells,6 and in rat tail arteries and veins.7 In preliminary studies, we found that kinins contribute to the release of nitrite from large coronary arteries and microvessels caused by agonists such as norepinephrine and A23187.8 In addition, recent studies have suggested that a kininlike activity can be released from isolated perfused hearts.9 Therefore, our second goal was to determine the role of local kinins in nitrite release from dog coronary blood vessels after administration of various angiotensins.
Recently, angiotensin receptors have been subcategorized into type 1 (AT1) and type 2 (AT2) based on function and the use of specific antagonists.10 Our final goal in this study was to determine whether stimulation of one of these angiotensin receptor subtypes selectively was responsible for nitrite release in dog coronary blood vessels or whether different fragments activate the same receptor to release nitrite.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Dogs were killed and the hearts removed for in vitro studies. These protocols were approved by the Institutional Animal Care and Use Committee of New York Medical College and conformed to the guiding principles of the American Physiological Society and the National Institutes of Health.
Isolation of Coronary Microvessels and Large Coronary Arteries
The heart was obtained immediately from
pentobarbital-anesthetized dogs and kept in ice-cold phosphate-buffered
saline (PBS) containing 0.1% bovine serum albumin at pH 7.4. All
subsequent steps were performed in ice-cold PBS unless indicated. Large
coronary arteries were freed of fat and adhering connective tissue and
saved in ice-cold PBS. These procedures have been published in
preliminary form.8 11
For isolation of coronary microvessels, the left ventricular free wall was freed from fat, connective tissue, epicardium, endocardium, and large coronary vessels. Coronary microvessels were obtained from the remaining myocardium by a series of steps involving sequential dissection, mincing, homogenization, sieving, and glass bead purification with the use of the method of Gerritsen and Printz.12
Briefly, the myocardium was cut with scissors into small pieces, chopped with a tissue chopper (McIlwain), and suspended in ice-cold PBS. The resulting suspension was homogenized for 50 seconds at the maximum speed. The homogenates were poured over a 100-µm nylon mesh sieve (Tetko), and the reddish-brown material that adhered to the nylon mesh was collected. Collected tissue was washed thoroughly and diluted with buffer. With the use of a clean sieve each time, the sieving steps were repeated several times. Phase-contrast microscopy showed that the sieved material was a mixture of myocytes, connective tissue, collagen fibers, and small branching vessels. The final suspension resulting from this step was gently homogenized with a glass homogenizer (Kontes, Dounce, 40-mL capacity). Care was taken not to damage the cells and was used to free the myocytes from the microvessels. This step was repeated two or three times. The resulting homogenates were poured through a column of glass beads (2- to 3-mm diameter, Corning) and washed carefully with PBS. The beads and adherent microvessels were poured into a beaker that contained ice-cold PBS and were stirred. Suspended microvessels were sieved through 80-µm nylon mesh and collected. A portion of each preparation was stained and observed under the microscope to ensure the purity of the preparation.
Studies With Microvessels
Microvessels were placed in a small package of 80-µm
nylon mesh, transferred into a tissue bath containing PBS, and
oxygenated with 95% O2 and 5% CO2 for 30
minutes. Tissue (20 mg wet weight) was placed in 5-mL plastic tubes
that contained 500 µL of PBS as control or 50 µL of each drug,
which was added to buffer and resulted in a total volume of 500
µL.
Preparation and Study of Large Coronary Arteries
Circumflex and left anterior descending coronary arteries were
isolated and freed of fat and connective tissue. During isolation and
dissection, care was taken to prevent tissue damage, and the entire
procedure was carried out in ice-cold PBS. Arteries were cut into small
rings, collected in a small package as for microvessels, and
transferred to the tissue bath for 30 minutes of oxygenation. The same
procedure was carried out for measurement of nitrite from large
coronary arteries as was described for microvessels.
Ang II (Ang-[1-8])
Ang II (10-8 to 10-5 mol/L) was
incubated with 20 mg of coronary microvessels or large arteries for 20
minutes, and nitrite formation was measured.
N-Nitro-L-arginine methyl ester
(L-NAME, 100 µmol/L), a competitive inhibitor of NO synthase; Hoe 140
(10 µmol/L), a bradykinin B2 receptor antagonist; the
protease inhibitor aprotinin (500 kallikrein inhibiting units
[KIU]/mL); or soybean trypsin inhibitor (100 µmol/L) was added to
the tubes before incubation of the tissue with 10-5 mol/L
Ang II. Nitrite formation was measured. In another group of vessels
before addition of the highest dose of Ang II, 10 µmol/L of DuP 753
(losartan), an AT1 receptor antagonist; saralasin, an
AT1 and AT2 antagonist; or PD 123319, an
AT2 antagonist, was added to the tubes, and nitrite release
was measured. Similar doses of angiotensins and antagonists were
studied for other angiotensin fragments; each protocol will be
discussed briefly below.
Ang I (Ang-[1-10])
Ang I (10-8 to 10-5 mol/L) was
incubated with the PBS containing coronary microvessels or large
arteries, and nitrite release was measured. L-NAME, Hoe 140, aprotinin,
soybean trypsin inhibitor, DuP 753, saralasin or PD 123319 was
incubated with the tissue before addition of 10-5 mol/L
Ang I and measurement of nitrite. For determination of the potential
conversion of Ang I to Ang II, ramiprilat (10 µmol/L) was incubated
with microvessels alone and in the presence of 10-5 mol/L
Ang I, and nitrite was measured.
Ang III (Ang-[2-8])
Ang III (10-8 to 10-5 mol/L) was
incubated with microvessels and large arteries, and nitrite was
measured. L-NAME, Hoe 140, aprotinin, soybean trypsin inhibitor, DuP
753, saralasin, or PD 123319 was added to tissue before the highest
dose of Ang III, and nitrite was measured.
Ang IV (Ang-[3-8])
Ang IV (10-8 to 10-5 mol/L) was added
to microvessels and large arteries, and nitrite was measured. To block
nitrite formation, L-NAME, Hoe 140, aprotinin, soybean trypsin
inhibitor, DuP 753, saralasin, or PD 123319 was used.
Ang-(1-7)
Ang-(1-7) (10-8 to 10-5 mol/L) was
added to microvessels and large arteries, and nitrite formation was
measured. L-NAME, Hoe 140, DuP 753, or saralasin was added to the
tissue before addition of the highest dose of Ang-(1-7), and nitrite
formation was measured.
Drugs and Chemicals
All angiotensin fragments (Ang I, III, IV, and Ang-[1-7]) were
purchased from Peninsula Laboratories, Inc. Hoe 140 was generously
supplied by Hoechst-Roussell Inc and PD 123319 by Parke-Davis Inc.
Losartan (DuP 753) was generously supplied by EI Du Pont de Nemours &
Co. Ang II and all other drugs and chemicals were purchased from Sigma
Chemical Co and were prepared fresh each day and used immediately.
Statistical Analysis and Calculation of Nitrite Release
Nitrite was measured with the use of the Griess reaction. For
each experiment two sets of standard curves were prepared using tubes
containing 500 µL of 0, 1, 2.5, 5, 7.5, and 10 µmol/L
NaNO2. N-(1-Naphthyl)ethylenediamine (50 µL of
0.2%) and sulfanilamide (450 µL of 0.1%) were added to each tube
containing standard or sample and vortexed for a few seconds. The tubes
were kept at room temperature for 5 to 10 minutes for development of
full pink color. Absorbance was measured at 540 nm with a
spectrophotometer (model 930, Uvikon) that was calibrated to zero with
the blank solution. Nitrite absorbance was computed with the use of
regression analysis (y=a+bx) and
converted to a straight line. Only curves with a correlation
coefficient >.95 were used. Nitrite absorbance produced by
microvessels or large coronary arteries was calculated with the
least-squares equation derived from the standard curve. Data are
expressed as mean±SEM. All of the graphs were produced with
SIGMA PLOT. Differences from control were determined with
Student's t test. A value of P<.05 was
considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Coronary microvessels were collected from normal dogs (n=16) with a mean body weight of 20.5±1.0 kg, heart weight of 190±11 g, left ventricular weight of 75±5 g, and microvessel weight of 1.65±0.20 g.
Fig 1 shows changes in nitrite production from control in coronary microvessels in response to increasing doses of Ang I, II, III, IV, and Ang-(1-7). Nitrite formation was increased significantly (P<.05) by 103±5, 145±17, 84±4, 107±16, and 70±3 pmol/mg after incubation of tissue for 20 minutes (37°C) with the highest dose of Ang I, II, III, IV, and Ang-(1-7), respectively. A small basal release of nitrite occurred during the 20-minute incubation with no agonist present, amounting to 25 to 40 pmol/mg per 20 minutes, essentially the equivalent of 10-8 mol/L of angiotensins as shown in Fig 1. Some of this release may be caused by nitrite present in the water used to prepare the buffer, because the antagonists such as L-NAME and Hoe 140 never lowered nitrite completely to zero (Fig 2).
|
|
Ang II
Nitrite production was increased by 145±17 pmol/mg per 20 minutes
in response to 10-5 mol/L Ang II (Fig 2, top). Nitrite
release was reduced significantly (P<.05) from 145±17 to
43±2, 39±9, 55±6, and 39±4 pmol/mg per 20 minutes by L-NAME, Hoe
140, aprotinin, and soybean trypsin inhibitor, respectively. Nitrite
production was reduced from 145±17 to 23±2, 25±2, and 39±4 pmol/mg
by DuP 753, saralasin, and PD 123319, respectively (Fig 2, bottom). We
did not determine whether there were additive effects of combining PD
123319 and DuP 753 because saralasin had effects that were similar to
those of these two antagonists. It is curious that all of the receptor
antagonists had the same effect regardless of whether the antagonist
was AT1 selective, AT2 selective, or
nonselective. We have no explanation for this observation unless the
antagonists are not selective or there is some interaction between the
receptors.
Ang I (Ang-[1-10])
Fig 3 (top) shows nitrite release in response to
10-5 mol/L Ang I. Nitrite production with
10-5 mol/L Ang I was reduced from 103±5 pmol/mg per 20
minutes (P<.05) to 31±4 with L-NAME, 40±4 with Hoe 140,
40±3 with soybean trypsin inhibitor, and 16±2 with aprotinin. Fig 3
(bottom) also shows changes in nitrite release by the highest dose of
Ang I alone or in the presence of DuP 753, saralasin, or PD 123319.
These antagonists reduced nitrite release from 103±5 to 25±2, 33±3,
and 21±2 pmol/mg per 20 minutes (P<.05), respectively.
|
Ramiprilat by itself increased nitrite production from 62±9 to 100±17 pmol/mg per 20 minutes (P<.05), which was partially blocked by Hoe 140 (to 80±10 pmol/mg per 20 minutes). Ang I increased nitrite to 164±27 pmol/mg per 20 minutes and in the presence of ramiprilat to only 123±14 pmol/mg per 20 minutes (P<.05 compared with Ang I alone). Thus, a significant portion of the increase in nitrite with Ang I depends on Ang I conversion to Ang II.
Ang III (Ang-[2-8])
Fig 4, top, shows nitrite formation from coronary
microvessels in response to 10-5 mol/L Ang III. Ang III
increased nitrite release by 84±4 pmol/mg per 20 minutes, and this
release was reduced to 28±3, 9±1, 30±5, and 23±4 by L-NAME, Hoe
140, aprotinin, and soybean trypsin inhibitor, respectively. DuP 753,
saralasin, and PD 123319 also reduced nitrite release significantly
(P<.05) from 74±6 to 20±2, 40±3, and 44±4 pmol/mg per
20 minutes, respectively.
|
Ang IV (Ang-[3-8])
The effects of 10-5 mol/L Ang IV on the nitrite
production from coronary microvessels are shown in Fig 5
(top). Ang IV increased nitrite release by 107±16 pmol/mg per 20
minutes. L-NAME, Hoe 140, aprotinin, and soybean trypsin inhibitor
reduced nitrite release to 25±4, 18±3, 32±8, and 15±3 pmol/mg,
respectively, but DuP 753 had no effect. Saralasin and PD 123319 (Fig 5, bottom) reduced nitrite release to 30±3 and 22±4 pmol/mg
(P<.05), respectively, and DuP 753 again had no effect.
|
Ang-(1-7)
Fig 6 shows that nitrite release increased by 54±4
pmol/mg in response to 10-5 mol/L Ang-(1-7). Release was
reduced significantly (P<.05) to 25±2, 24±2, 19±1, and
23±3 pmol/mg by L-NAME, Hoe 140, DuP 753, and saralasin,
respectively.
|
Effects of Angiotensin Fragments on Large Coronary Artery Nitrite
Production
The Table summarizes the effects of Ang II and
fragments on nitrite release in large coronary arteries. Nitrite
production from large coronary arteries was dose related and reduced
when L-NAME, Hoe 140, aprotinin, soybean trypsin inhibitor, DuP 753, or
PD 123319 was incubated with the tissue before addition of
10-5 mol/L of angiotensins. All of the results were
qualitatively similar to those obtained with microvessels.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The results of the present study indicate that Ang I, Ang II, and their fragments (Ang III, Ang IV, and Ang-[1-7]) increased nitrite release in isolated coronary microvessels and large coronary arteries from the normal dog heart. Nitrite production was dose related and attenuated by L-NAME, a competitive inhibitor of NO synthase. Surprisingly, Hoe 140, a specific bradykinin B2 receptor antagonist, and the protease inhibitors soybean trypsin inhibitor and aprotinin also inhibited angiotensin-stimulated nitrite release, suggesting that the NO release depended on the formation of local kinins and stimulation of bradykinin B2 receptors.
Nitrite formation in response to Ang I, II, III, and Ang-(1-7) was reduced significantly by DuP 753 (losartan), an AT1 receptor antagonist; saralasin, an AT1 and AT2 receptor antagonist; and PD 123319, a selective AT2 receptor antagonist. Ang IV–stimulated nitrite release was reduced by both saralasin and PD 123319 but not by DuP 753. Therefore, the results of the present study lead us to speculate that there is link between angiotensin receptors—possibly on the membrane of endothelial cells in the coronary vascular bed—the production of kinins through activation of a local kallikrein-kinin system in coronary blood vessels, and NO synthesis and release.
According to the classic view,1 2 the renin-angiotensin system has a variety of physiological actions in the cardiovascular system. Circulating renin acts on angiotensinogen in blood or locally to form Ang I, a biologically inactive decapeptide. Ang I is converted to the active octapeptide Ang II, which is among the most potent of vasoconstrictors, by angiotensin-converting enzyme located on the luminal surface of vascular endothelial cells. Ang II can be converted to Ang III by the action of an aminopeptidase. Ang II and III are converted enzymatically to a series of fragments that were thought to be biologically inactive. However, recent studies have challenged this notion. Swanson et al4 have reported the existence of a specific binding site for Ang IV distinct from either Ang II or III receptors. Ang-(1-7) is another biologically active peptide that can be formed from either Ang II or Ang I.3
Although Ang II is a vasoconstrictor, recent studies suggest that Ang II and various angiotensin fragments may also stimulate the production of endothelium-derived relaxing factors. Hasegawa et al13 have found in domestic fowl that Ang II reduced blood pressure in vivo and caused endothelium-dependent relaxation of aortic smooth muscle in vitro that resembled the effects of acetylcholine. L-NAME decreased the vasorelaxant effect of both Ang II and acetylcholine. Stallone et al14 suggested that Ang II has specific receptors on the membrane of vascular endothelial cells that mediate a vasodepressor response in vivo and endothelium-dependent relaxation of aortic rings in vitro. Haberl et al15 have shown that Ang III and IV cause endothelium-dependent dilation of rabbit cerebral arterioles independent of prostaglandin synthesis. Ang IV, which lacks the amino-terminal L-arginine residue, had no effect on cerebral arterioles when applied topically, but when it was used after application of L-arginine, it induced dilation. The vasodilator effect of angiotensin fragments was eliminated by methylene blue, a known inhibitor of guanylate cyclase. Osei et al16 have reported a selective regional vascular response to Ang-(1-7). This angiotensin fragment produced dose- and region-dependent vasodilation and vasoconstriction in the mesenteric and hindquarter vascular beds of the cat. The vasoconstriction was eliminated by DuP 753, an AT1 receptor antagonist. The vasodilation was partially blocked by L-NAME but not by the cyclooxygenase inhibitor meclofenamate. Therefore, this study also suggested that the vasodilator response in cat mesentery and hindquarters was mediated through NO.
Receptor binding assays and molecular cloning have shown that Ang II has multiple receptors. The vasoconstrictor effect of Ang II in blood vessels is mediated through the AT1 receptor and can be inhibited by DuP 753.17 18 Our study indicates that nitrite formation from isolated coronary microvessels and large arteries in response to Ang I, Ang II, and their fragments Ang III and Ang-(1-7) was attenuated by DuP 753. These results lead us to speculate that activation of the AT1 receptor by angiotensins is also linked to the local production of kinins and stimulation of NO synthase. Hence, NO release may buffer the vasoconstriction or even cause vasodilation of the blood vessels in response to angiotensins. Inhibition of nitrite release by L-NAME, a competitive NO synthase inhibitor, Hoe 140, and the protease inhibitors soybean trypsin inhibitor and aprotinin, which block bradykinin B2 receptors and the enzymic formation of bradykinin locally, also supports our conclusion that angiotensins indirectly release NO.
Several lines of evidence suggest that AT1 receptors are divided into two different subtypes, AT1a and AT1b.17 These receptor subtypes are structurally if not functionally different. Since DuP 753 blocks both receptor subtypes, it was difficult to determine the receptor subtype that stimulated endothelium-derived relaxing factor release in the present study. It seems that the AT1b receptor subtype has a higher affinity for PD 123319 than for DuP 753. The AT2 receptor has been cloned recently.19 20 Wiemer et al21 have found in bovine aortic endothelial cells and isolated ischemic rat hearts that Ang II was able to increase NO synthesis and release. Their data indicated the existence of Ang II receptors on the membrane of vascular endothelial cells. NO release was blocked with the use of L-NAME and Hoe 140, and this blockage was concomitant with complete inhibition of the increase in endothelial cell cGMP. Their data are consistent with our own. Taken together, the results of these experiments indicate that release of NO/nitrite in response to Ang II is most likely mediated through the local production of kinins.
Swanson et al4 first discovered Ang IV (Ang-[3-8]) in bovine adrenal cortical cells. This fragment has a high affinity for membrane binding sites in many species and tissues. It binds specifically, reversibly, and saturably and has a low affinity for Ang II and III receptors. Ang IV may cause endothelium-dependent vasodilation. Our data indicate that Ang IV can cause NO release from coronary microvessels and large arteries. Nitrite release was blocked by L-NAME, Hoe 140, saralasin, PD 123319, soybean trypsin inhibitor, and aprotinin but not by DuP 753. Blockade by Hoe 140 and the protease inhibitors indicates that nitrite release in response to Ang IV is mediated through the local generation of kinins. Blockade by saralasin and PD 123319 but not DuP 753 indicates that kinin formation is initiated through the AT2 receptor. Other recent studies by Jarvis et al22 have suggested that Ang IV can compete for a low-affinity binding site with Ang II in the presence of DuP 753 in bovine adrenal cortical cells. This binding was not blocked by AT2 receptor antagonists, and the authors concluded that this may indicate the presence of a unique angiotensin receptor, AT4. In our blood vessel preparations, the effects of Ang IV were selectively blocked by PD 123319, indicating a potential role for an AT2 receptor. The difference in these two studies may be due to differences in tissue type, the concentration of the agonists and antagonists, or some fundamental difference in the expression of angiotensin receptor subtypes in tissues.
Ferrario et al3 have reported the existence of Ang-(1-7), which is produced directly from Ang I by an enzymatic reaction distinct from angiotensin-converting enzyme, in the canine and rat brain. This fragment is derived from the amino terminal of Ang I or II and is biologically active. This fragment is as potent as Ang II as a stimulus for the secretion of hypophyseal hormones, ie, vasopressin, but lacks the direct pressor and dypsogenic effects of Ang II. Our data also revealed that Ang-(1-7) can cause nitrite release from coronary microvessels and large coronary arteries that was blocked by Hoe 140, the protease inhibitors, and both AT1 and AT2 receptor antagonists. Thus, nitrite release also depends on the generation of local kinins but not on any specific angiotensin receptor subtype.
In our studies we attempted to determine whether the release of nitrite by Ang I was due to conversion to Ang II or was a direct effect of this peptide. To answer this question, we incubated Ang I with a converting enzyme inhibitor, ramiprilat, before measuring nitrite. Ramiprilat by itself, and in hindsight we suspect most other angiotensin-converting enzyme inhibitors, released nitrite, which was blocked by both L-NAME and Hoe 140. Ang I increased nitrite production significantly from 62 to 164 pmol/mg per 20 minutes or by 165%. Ramiprilat increased nitrite from 62 to 100 pmol/mg per minute, and in the presence of both ramiprilat and Ang I, nitrite increased to 123 pmol/mg per minute, ie, by only 23%. Thus it appears that a substantial portion of the nitrite release in response to Ang I is blocked by ramiprilat; there is some concern, however, in interpreting this finding because ramiprilat by itself had such dramatic effects on baseline nitrite production. We are more certain that appreciable amounts, certainly not predominant amounts, of Ang IV were not formed in vitro because this was the only peptide whose ability to stimulate nitrite was selectively blocked by an AT2 receptor antagonist and not affected by DuP 753.
Since the release of nitrite by all of the angiotensins was inhibited by both soybean trypsin inhibitor and aprotinin, our data suggest that angiotensins activate a plasma kallikrein-like enzyme. Because our tissues are extensively washed during preparation, it is unlikely that there is enough plasma in our preparation for the kallikrein to be just a contaminant. On the other hand, plasma kallikrein may specifically bind to the plasma membrane of the endothelial cell, or it could be incorporated into vesicles by pinocytosis. This is an area of active investigation currently in our laboratory; the exact location of this plasmalike kallikrein is not yet clear.
Some caution should be exerted when evaluating the role indicated by our data of AT1 and AT2 receptors in NO release. We used high doses of the antagonists, so there may be some nonspecificity, especially for PD 123319. However, there appeared to be some selectivity at these doses, because the response to Ang IV was selectively blocked by the AT2 antagonist (Fig 5) at the doses used. In addition, we used high doses of all agonists in our study to elicit significant nitrite release. This may indicate that high nonphysiological levels of angiotensins are needed to activate local kinin and NO production or more likely that there are enzymes present, as evidenced by the presence of angiotensin-converting enzyme in our study, which metabolizes angiotensins.
In summary, there is a local kinin-generating system in isolated coronary microvessels and large coronary arteries that stimulates NO synthesis, measured as nitrite in vitro. Nolly et al7 have shown the existence of a kallikrein or kallikrein-like enzyme in the tail arteries and veins of the rat. In our study, Ang I, Ang II, and their fragments Ang III, Ang IV, and Ang-(1-7), acting via specific receptors, caused activation of the vascular kallikrein-kinin system, generation of bradykinin or a bradykinin-like substance, and release of NO. Although the function of vascular kinins is not clear yet, there is already much evidence that angiotensin-converting enzyme inhibitors block the breakdown of kinins in the vascular wall and increase nitrite release, as in our study, and that a significant portion of the antihypertensive effects of these drugs may be due to the local formation of kinins and subsequent NO release.23
|
Acknowledgments |
|---|
This work was supported by PO-HL-43023, HL-18579, HL-50142, and HL-53053 from the National Heart, Lung, and Blood Institute. We would like to thank Hoechst-Roussel for the generous supply of Hoe 140, EI Du Pont de Nemours for the supply of DuP 753, and Parke-Davis for the supply of PD 123319.
Received March 2, 1995; first decision April 3, 1995; accepted April 3, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Haber E. The renin-angiotensin system and hypertension. Kidney Int. 1979;15:427-444. [Medline] [Order article via Infotrieve]
2. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med. 1974;291:389-401.
3. Ferrario CM, Barnes KL, Block CH, Brosnihan KB, Diz DI, Khosla MC, Santos RAS. Pathways of angiotensin formation and function in the brain. Hypertension. 1990;15(suppl I):I-13-I-19.
4. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JKM, Wright JW, Hall KL, Miller-Wing AV, Stobb JW, Cook VI, Harding EC, Harding JW. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept. 1992;40:409-419. [Medline] [Order article via Infotrieve]
5. Mombouli JV, Vanhoutte PM. Kinins mediate kallikrein induced endothelium dependent relaxations in isolated canine coronary artery. Biochem Biophys Res Commun. 1992;185:693-697. [Medline] [Order article via Infotrieve]
6.
Iwaarden FV, de Groot PG, Sixma JJ, Berrettini M,
Bouma BN. High molecular weight kininogen is present in
cultured human endothelial cells: localization, isolation and
characterization. Blood. 1988;71:1268-1276.
7.
Nolly H, Carretero OA, Scicli G, Madeddu P, Scicli AG.
A kallikrein-like enzyme in blood vessels of one kidney, one
clip hypertensive rat. Hypertension. 1990;16:436-440.
8. Seyedi N, Nasjletti A, Xu X, Wolin MS, Hintze TH. NO/nitrite modulation of vasoconstrictor agents norepinephrine and angiotensin II but not endothelin from canine coronary microvessels and large arteries is due to local kinin production. Circulation. 1993;88(suppl I):I-470. Abstract.
9. Zeitlin IJ, Fagbemi SO, Parratt JR. Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity. Cardiovasc Res. 1990;23:91-99.
10. Timmermans P, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-250. [Medline] [Order article via Infotrieve]
11. Seyedi N, Shen W, Wang J, Gerritsen ME, Wolin MS, Hintze TH. Reduction in release of nitrite from microvessels and large coronary arteries of the left ventricle during heart failure. Circulation. 1992;86(suppl I):I-763. Abstract.
12.
Gerritsen ME, Printz M. Sites of
prostaglandin synthesis in the bovine heart and isolated
coronary microvessels. Circ Res. 1981;49:1152-1163.
13.
Hasegawa K, Nishimura H, Khosla MC. Angiotensin
II induced endothelium dependent relaxation of fowl aorta.
Am J Physiol. 1993;264:R903-R911.
14. Stallone JN, Nishimura H, Nasjletti A. Angiotensin II binding sites in aortic endothelium of domestic fowl. Am J Physiol. 1990;258:E777-E782.
15.
Haberl RL, Decker PJ, Einhaupl KM. Angiotensin
degradation products mediate endothelium dependent dilation of rabbit
brain arterioles. Circ Res. 1991;68:1621-1627.
16. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin (1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993;234:35-42. [Medline] [Order article via Infotrieve]
17. Chiu AT, McCall DE, Ardecky RJ, Duncia JV, Nguyen TT, Timmermans PBMWM. Angiotensin II receptors subtypes and their selective nonpeptide ligands. Receptor. 1990;10:33-40.
18. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5:221S-235S. [Medline] [Order article via Infotrieve]
19.
Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui
H, Hamakubo T, Inagami T. Molecular cloning of a novel
angiotensin II receptor isoform involved in phosphotyrosine phosphatase
inhibition. J Biol Chem. 1993;268:24543-24546.
20.
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt
R, Dzau VJ. Expression cloning of type 2 angiotensin II
receptors reveals a unique class of seven-transmembrane
receptors. J Biol Chem. 1993;268:24539-24542.
21. Wiemer G, Scholkens BA, Busse R, Wagner A, Heitsch H, Linz W. The functional role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett. 1993;3:24-27.
22. Jarvis MF, Gesser GW, Ly CQ. The angiotensin hexapeptide 3-8 fragment potently inhibits 125I angiotensin II binding to non-AT1 or AT2 recognition sites in bovine adrenal cortex. Eur J Pharmacol. 1992;219:319-322. [Medline] [Order article via Infotrieve]
23.
Cachofeiro V, Sakakibara T, Nasjletti A. Kinins,
nitric oxide, and the hypotensive effect of captopril and ramiprilat in
hypertension. Hypertension. 1992;19:138-145.
This article has been cited by other articles:
 |
|
 |
|
  P. Castro-Chaves, R. Fontes-Carvalho, M. Pintalhao, P. Pimentel-Nunes, and A. F. Leite-Moreira Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart Exp Physiol, June 1, 2009; 94(6): 665 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Sullivan Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1220 - R1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pignone, A. D. Rosso, K B. Brosnihan, F. Perfetto, R. Livi, G. Fiori, S. Guiducci, M. Cinelli, V. Rogai, A. Tempestini, et al. Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control Ann Rheum Dis, October 1, 2007; 66(10): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Kim, X. Zhang, X. Xu, A. Chen, J. B. Gonzalez, S. Koul, K. Vijayan, G. J. Crystal, S. F. Vatner, and T. H. Hintze Evidence for enhanced eNOS function in coronary microvessels during the second window of protection Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2152 - H2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rzewuska-Lech, M. Jayachandran, L. A. Fitzpatrick, and V. M. Miller Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E105 - E112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Gurzu, M. Costuleanu, S. M. Slatineanu, A. Ciobanu, and G. Petrescu Are Multiple Angiotensin Receptor Types Involved in Angiotensin (1-7) Actions on Isolated Rat Portal Vein? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 90 - 95. [Abstract] [PDF]
|
|
|
|
 |
|
 D. You, L. Loufrani, C. Baron, B. I. Levy, R. E. Widdop, and D. Henrion High Blood Pressure Reduction Reverses Angiotensin II Type 2 Receptor-Mediated Vasoconstriction Into Vasodilation in Spontaneously Hypertensive Rats Circulation, March 1, 2005; 111(8): 1006 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Somoza, M. C. Gonzalez, J. M. Gonzalez, F. Abderrahim, S. M. Arribas, and M. S. Fernandez-Alfonso Modulatory role of the adventitia on noradrenaline and angiotensin II responses: Role of endothelium and AT2 receptors Cardiovasc Res, February 1, 2005; 65(2): 478 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Campbell, H. Krum, and M. D. Esler Losartan Increases Bradykinin Levels in Hypertensive Humans Circulation, January 25, 2005; 111(3): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gironacci, M. S. Valera, I. Yujnovsky, and C. Pena Angiotensin-(1-7) Inhibitory Mechanism of Norepinephrine Release in Hypertensive Rats Hypertension, November 1, 2004; 44(5): 783 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bergaya, R. H.P. Hilgers, P. Meneton, Y. Dong, M. Bloch-Faure, T. Inagami, F. Alhenc-Gelas, B. I. Levy, and C. M. Boulanger Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT2 Receptors Circ. Res., June 25, 2004; 94(12): 1623 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Liu, X.-P. Yang, E. G. Shesely, S. S. Sankey, and O. A. Carretero Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1473 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yayama, M. Horii, H. Hiyoshi, M. Takano, H. Okamoto, S. Kagota, and M. Kunitomo Up-Regulation of Angiotensin II Type 2 Receptor in Rat Thoracic Aorta by Pressure-Overload J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.P. Mason, P. Marche, and T.H. Hintze Novel Vascular Biology of Third-Generation L-Type Calcium Channel Antagonists: Ancillary Actions of Amlodipine Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2155 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Itoh, J. Kajikuri, T. Tada, Y. Suzuki, and Y. Mabuchi Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries J. Physiol., May 1, 2003; 548(3): 893 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Garg and K. N. Pandey Angiotensin II-Mediated Negative Regulation of Npr1 Promoter Activity and Gene Transcription Hypertension, March 1, 2003; 41(3): 730 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kurisu, R. Ozono, T. Oshima, M. Kambe, T. Ishida, H. Sugino, H. Matsuura, K. Chayama, Y. Teranishi, O. Iba, et al. Cardiac Angiotensin II Type 2 Receptor Activates the Kinin/NO System and Inhibits Fibrosis Hypertension, January 1, 2003; 41(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cai, Z. Li, S. Dikalov, S. M. Holland, J. Hwang, H. Jo, S. C. Dudley Jr., and D. G. Harrison NAD(P)H Oxidase-derived Hydrogen Peroxide Mediates Endothelial Nitric Oxide Production in Response to Angiotensin II J. Biol. Chem., December 6, 2002; 277(50): 48311 - 48317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wiemer, L. W. Dobrucki, F. R. Louka, T. Malinski, and H. Heitsch AVE 0991, a Nonpeptide Mimic of the Effects of Angiotensin-(1-7) on the Endothelium Hypertension, December 1, 2002; 40(6): 847 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, O. A. Carretero, Y.-H. Liu, E. G. Shesely, F. Yang, A. Kapke, and X.-P. Yang Role of AT2 Receptors in the Cardioprotective Effect of AT1 Antagonists in Mice Hypertension, September 1, 2002; 40(3): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Adamy, P. Oliviero, S. Eddahibi, L. Rappaport, J.-L. Samuel, E. Teiger, and C. Chassagne Cardiac modulations of ANG II receptor expression in rats with hypoxic pulmonary hypertension Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H733 - H740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. G. Braga, M. Da Silva Lemos, J. R. Da Silva, W. R. P. Fontes, and R. Augusto Souza Dos Santos Effects of angiotensins on day-night fluctuations and stress-induced changes in blood pressure Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1663 - R1671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Lorenzo, M. Ruiz-Ortega, Y. Suzuki, M. Ruperez, V. Esteban, T. Sugaya, and J. Egido Angiotensin III Activates Nuclear Transcription Factor-{kappa}B in Cultured Mesangial Cells Mainly via AT2 Receptors: Studies with AT1 Receptor-Knockout Mice J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1162 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Han, S. Hoffmann, K. Hu, and G. Ertl Angiotensin II subtype 1 (AT1) receptors contribute to ischemic contracture and regulate chemomechanical energy transduction in isolated transgenic rat ({alpha}MHC-hAT1)594-17 hearts Eur J Heart Fail, March 1, 2002; 4(2): 131 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moreno, A. Lopez, M. T. Llinas, F. Rodriguez, A. Lopez-Farre, E. Nava, and F. J. Salazar Changes in NOS activity and protein expression during acute and prolonged ANG II administration Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2002; 282(1): R31 - R37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Henrion, N. Kubis, and B. I. Levy Physiological and Pathophysiological Functions of the AT2 Subtype Receptor of Angiotensin II: From Large Arteries to the Microcirculation Hypertension, November 1, 2001; 38(5): 1150 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, J. P. J. Halcox, M. A. Waclawiw, and A. A. Quyyumi Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sasaki, Y. Higashi, K. Nakagawa, H. Matsuura, G. Kajiyama, and T. Oshima Effects of Angiotensin-(1-7) on Forearm Circulation in Normotensive Subjects and Patients With Essential Hypertension Hypertension, July 1, 2001; 38(1): 90 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I Jugdutt and M. Balghith Enhanced regional AT2-receptor and PKC{varepsilon} expression during cardioprotection induced by AT1-receptor blockade after reperfused myocardial infarction Journal of Renin-Angiotensin-Aldosterone System, June 1, 2001; 2(2): 134 - 140. [Abstract] [PDF]
|
|
|
|
|
|
R. Bravo, B. Somoza, M. Ruiz-Gayo, C. Gonzalez, L. M. Ruilope, and M. S. Fernandez-Alfonso Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats Hypertension, May 1, 2001; e10(5): . [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bergaya, P. Meneton, M. Bloch-Faure, E. Mathieu, F. Alhenc-Gelas, B. I. Levy, and C. M. Boulanger Decreased Flow-Dependent Dilation in Carotid Arteries of Tissue Kallikrein-Knockout Mice Circ. Res., March 30, 2001; 88(6): 593 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz and G. Heusch Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S136 - S140. [PDF]
|
|
|
|
|
|
B. I Jugdutt, Yi Xu, M. Balghith, and V. Menon Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2 receptor Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S162 - S166. [Abstract] [PDF]
|
|
|
|
|
|
H. Heitsch, S. Brovkovych, T. Malinski, and G. Wiemer Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells Hypertension, January 1, 2001; 37(1): 72 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Kudej, X.-P. Zhang, B. Ghaleh, C.-H. Huang, J. B. Jackson, A. B. Kudej, N. Sato, S. Sato, D. E. Vatner, T. H. Hintze, et al. Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigs Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2967 - H2974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chabielska, T. Matys, I. Kucharewicz, D. Pawlak, R. Rolkowski, and W. Buczko The involvement of AT2-receptor in the antithrombotic effect of losartan in renal hypertensive rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 263 - 267. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Kraiczi, J. Hedner, Y. Peker, and J. Carlson Increased vasoconstrictor sensitivity in obstructive sleep apnea J Appl Physiol, August 1, 2000; 89(2): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, S. Konig, B. Wittig, and J. Egido Angiotensin II Activates Nuclear Transcription Factor {kappa}B Through AT1 and AT2 in Vascular Smooth Muscle Cells : Molecular Mechanisms Circ. Res., June 23, 2000; 86(12): 1266 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Yi Xu, V. Menon, and B. I Jugdutt Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-{varepsilon} in acutely reperfused myocardial infarction in the dog: Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKC{varepsilon} proteins Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 184 - 195. [Abstract] [PDF]
|
|
|
|
|
|
M. M. Gironacci, M. Vatta, M. Rodriguez-Fermepin, B. E. Fernandez, and C. Pena Angiotensin-(1-7) Reduces Norepinephrine Release Through a Nitric Oxide Mechanism in Rat Hypothalamus Hypertension, June 1, 2000; 35(6): 1248 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad, T. Tupas-Habib, W. H. Schenke, R. Mincemoyer, J. A. Panza, M. A. Waclawin, S. Ellahham, and A. A. Quyyumi Acute and Chronic Angiotensin-1 Receptor Antagonism Reverses Endothelial Dysfunction in Atherosclerosis Circulation, May 23, 2000; 101(20): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lang, S. I. Mosfer, A. Shakesby, F. Donaldson, and M. J. Lewis Coronary Microvascular Endothelial Cell Redox State in Left Ventricular Hypertrophy : The Role of Angiotensin II Circ. Res., March 3, 2000; 86(4): 463 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Jugdutt, Yi Xu, M. Balghith, R. Moudgil, and V. Menon Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R, IP3R and PKC{varepsilon} Proteins and cGMP Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 301 - 311. [Abstract] [PDF]
|
|
|
|
|
|
X. RUAN, M. I. OLIVERIO, T. M. COFFMAN, and W. J. ARENDSHORST Renal Vascular Reactivity in Mice: AngII-Induced Vasoconstriction inAT1A Receptor Null Mice J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2620 - 2630. [Abstract] [Full Text]
|
|
|
|
|
|
K. C Wollert and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res, September 1, 1999; 43(4): 838 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Linz, P. Wohlfart, B. A Scholkens, T. Malinski, and G. Wiemer Interactions among ACE, kinins and NO Cardiovasc Res, August 15, 1999; 43(3): 549 - 561. [Full Text] [PDF]
|
|
|
|
|
|
G. Zhao, X. Zhang, C. J. Smith, X. Xu, M. Ochoa, D. Greenhouse, T. Vogel, C. Curran, and T. H. Hintze Reduced coronary NO production in conscious dogs after the development of alloxan-induced diabetes Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H268 - H278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Campbell, A. Kladis, T. A. Briscoe, and J. Zhuo Type 2 Bradykinin-Receptor Antagonism Does Not Modify Kinin or Angiotensin Peptide Levels Hypertension, May 1, 1999; 33(5): 1233 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yoshiyama, K. Takeuchi, T. Omura, S. Kim, H. Yamagishi, I. Toda, M. Teragaki, K. Akioka, H. Iwao, and J. Yoshikawa Effects of Candesartan and Cilazapril on Rats With Myocardial Infarction Assessed by Echocardiography Hypertension, April 1, 1999; 33(4): 961 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Johnson, C. Lucas, L. W. Stevenson, and M. A. Creager Effect of intensive therapy for heart failure on the vasodilator response to exercise J. Am. Coll. Cardiol., March 1, 1999; 33(3): 743 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Horiuchi, M. Akishita, and V. J. Dzau Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System Hypertension, February 1, 1999; 33(2): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Anderson, A. M. Devlin, D. Graham, J. J. Morton, C. A. Hamilton, J. L. Reid, N. J. Schork, and A. F. Dominiczak Telemetry for Cardiovascular Monitoring in a Pharmacological Study : New Approaches to Data Analysis Hypertension, January 1, 1999; 33(1): 248 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsubara Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases Circ. Res., December 14, 1998; 83(12): 1182 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jalowy, R. Schulz, H. Dorge, M. Behrends, and G. Heusch Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1787 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gorelik, L. A. Carbini, and A. G. Scicli Angiotensin 1-7 Induces Bradykinin-Mediated Relaxation in Porcine Coronary Artery J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 403 - 410. [Abstract] [Full Text]
|
|
|
|
|
|
L. V. d'Uscio, S. Shaw, M. Barton, and T. F. Luscher Losartan but Not Verapamil Inhibits Angiotensin II–Induced Tissue Endothelin-1 Increase : Role of Blood Pressure and Endothelial Function Hypertension, June 1, 1998; 31(6): 1305 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Liu, H. Murakami, and I. H. Zucker Angiotensin II–Nitric Oxide Interaction on Sympathetic Outflow in Conscious Rabbits Circ. Res., March 9, 1998; 82(4): 496 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang and T. H. Hintze Amlodipine Releases Nitric Oxide From Canine Coronary Microvessels : An Unexpected Mechanism of Action of a Calcium Channel–Blocking Agent Circulation, February 17, 1998; 97(6): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Handa, L. T. Krebs, J. W. Harding, and S. E. Handa Angiotensin IV AT4-receptor system in the rat kidney Am J Physiol Renal Physiol, February 1, 1998; 274(2): F290 - F299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pueyo, J.-F. Arnal, J. Rami, and J.-B. Michel Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells Am J Physiol Cell Physiol, January 1, 1998; 274(1): C214 - C220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sakakibara, T. H. Hintze, and A. Nasjletti Determinants of kinin release in isolated rat hindquarters Am J Physiol Regulatory Integrative Comp Physiol, January 1, 1998; 274(1): R120 - R125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Forfia, X. Zhang, F. Ochoa, M. Ochoa, X. Xu, R. Bernstein, P. B. Sehgal, N. R. Ferreri, and T. H. Hintze Relationship between plasma NOx and cardiac and vascular dysfunction after LPS injection in anesthetized dogs Am J Physiol Heart Circ Physiol, January 1, 1998; 274(1): H193 - H201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-P. Zou, F. Wu, and A. W. Cowley Jr Protective Effect of Angiotensin II-Induced Increase in Nitric Oxide in the Renal Medullary Circulation Hypertension, January 1, 1998; 31(1): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gohlke, C. Pees, and T. Unger AT2 Receptor Stimulation Increases Aortic Cyclic GMP in SHRSP by a Kinin-Dependent Mechanism Hypertension, January 1, 1998; 31(1): 349 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, G. A. Scicli, X. Xu, A. Nasjletti, and T. H. Hintze Role of Endothelial Kinins in Control of Coronary Nitric Oxide Production Hypertension, November 1, 1997; 30(5): 1105 - 1111. [Abstract] [Full Text]
|
|
|
|
|
|
C. V. Lima, R. D. Paula, F. L. Resende, M. C. Khosla, and R. A. S. Santos Potentiation of the Hypotensive Effect of Bradykinin by Short-term Infusion of Angiotensin-(1-7) in Normotensive and Hypertensive Rats Hypertension, September 1, 1997; 30(3): 542 - 548. [Abstract] [Full Text]
|
|
|
|
|
|
A. Abbas, G. Gorelik, L. A. Carbini, and A. G. Scicli Angiotensin-(1-7) Induces Bradykinin-Mediated Hypotensive Responses in Anesthetized Rats Hypertension, August 1, 1997; 30(2): 217 - 221. [Abstract] [Full Text]
|
|
|
|
|
|
G. Zhao, X. Zhang, X. Xu, M. Ochoa, and T. H. Hintze Short-term Exercise Training Enhances Reflex Cholinergic Nitric Oxide–Dependent Coronary Vasodilation in Conscious Dogs Circ. Res., June 19, 1997; 80(6): 868 - 876. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. Gironacci, P. S. Lorenzo, and E. Adler-Graschinsky Possible Participation of Nitric Oxide in the Increase of Norepinephrine Release Caused by Angiotensin Peptides in Rat Atria Hypertension, June 1, 1997; 29(6): 1344 - 1350. [Abstract] [Full Text]
|
|
|
|
|
|
X. Zhang, Y.-W. Xie, A. Nasjletti, X. Xu, M. S. Wolin, and T. H. Hintze ACE Inhibitors Promote Nitric Oxide Accumulation to Modulate Myocardial Oxygen Consumption Circulation, January 7, 1997; 95(1): 176 - 182. [Abstract] [Full Text]
|
|
|
|
|
|
P. Li, M. C. Chappell, C. M. Ferrario, and K. B. Brosnihan Angiotensin-(1-7) Augments Bradykinin-Induced Vasodilation by Competing With ACE and Releasing Nitric Oxide Hypertension, January 1, 1997; 29(1): 394 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. d'Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, and T. F. Luscher Effects of Chronic ETA-Receptor Blockade in Angiotensin II-Induced Hypertension Hypertension, January 1, 1997; 29(1): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gohlke, I. Kuwer, A. Schnell, K. Amann, G. Mall, and T. Unger Blockade of Bradykinin B2 Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, January 1, 1997; 29(1): 478 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maeso, J. Navarro-Cid, R. Munoz-Garcia, E. Rodrigo, L. M. Ruilope, V. Lahera, and V. Cachofeiro Losartan Reduces Phenylephrine Constrictor Response in Aortic Rings From Spontaneously Hypertensive Rats: Role of Nitric Oxide and Angiotensin II Type 2 Receptors Hypertension, December 1, 1996; 28(6): 967 - 972. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. Bernstein, F. Y. Ochoa, X. Xu, P. Forfia, W. Shen, C. I. Thompson, and T. H. Hintze Function and Production of Nitric Oxide in the Coronary Circulation of the Conscious Dog During Exercise Circ. Res., October 1, 1996; 79(4): 840 - 848. [Abstract] [Full Text]
|
|
|
|
|
|
P. Gohlke, W. Linz, B. A. Scholkens, G. Wiemer, and T. Unger Cardiac and Vascular Effects of Long-term Losartan Treatment in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, September 1, 1996; 28(3): 397 - 402. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Kichuk, N. Seyedi, X. Zhang, C. C. Marboe, R. E. Michler, L. J. Addonizio, G. Kaley, A. Nasjletti, and T. H. Hintze Regulation of Nitric Oxide Production in Human Coronary Microvessels and the Contribution of Local Kinin Formation Circulation, July 1, 1996; 94(1): 44 - 51. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. L. Goodfriend, M. E. Elliott, and K. J. Catt Angiotensin Receptors and Their Antagonists N. Engl. J. Med., June 20, 1996; 334(25): 1649 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Brosnihan, P. Li, and C. M. Ferrario Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide Hypertension, March 1, 1996; 27(3): 523 - 528. [Abstract] [Full Text]
|
|
|
|
|
|
H. G. Llambi, F. Manni, P. L. Padula, O.A. Carretero, and C.M. Taquini Myocardial Contractility Is Modulated by Angiotensin II via Nitric Oxide Hypertension, March 1, 1996; 27(3): 704 - 708. [Abstract] [Full Text]
|
|
|
|
|
|
H. Guan, V. Cachofeiro, M. L. Pucci, P. M. Kaminski, M. S. Wolin, and A. Nasjletti Nitric Oxide and the Depressor Response to Angiotensin Blockade in Hypertension Hypertension, January 1, 1996; 27(1): 19 - 24. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||